Key Dates

Related Announcements

• October 9, 2020 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). See NOFO PA-20-272

Issued by

National Cancer Institute (NCI)

Purpose

The National Cancer Institute (NCI) Center for Global Health (CGH) seeks to support impactful research that leverages scientific opportunities afforded by global collaboration. The purpose of this Notice of Special Interest (NOSI) is to highlight CGH’s interest in supporting studies aimed at fostering collaborations between researchers who are part of CGH’s funded research networks or partnering with researchers on CGH’s networks. This supplemental opportunity will support current awardees of CGH-led or co-led networks (see Eligibility section). Projects can include collaborations between current awardees within a CGH-led or co-led network, collaborations across networks between current awardees of CGH-led or co-led programs, and/or may include investigators who are not currently supported by the CGH research programs. Examples of collaborative projects that this NOSI could support include, but are not limited to, research needs assessment surveys and preliminary studies to extend research aims.

Note that projects facilitating new collaborations are of particular interest. Applicants are encouraged to consider how collaborative projects may enhance diverse perspectives within their project teams by introducing new investigators, ideas, and viewpoints.

The programmatic goals of each research program may differ; therefore, it is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.

Application and Submission Information

Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• All supplement requests must be submitted electronically through Grants.gov.
• Applicants are strongly encouraged to notify the NCI Program Director assigned to the parent award that a request has been submitted in response to this NOSI in order to facilitate efficient processing of the request.

Eligibility and Eligible Individuals (Program Director/Principal Investigator):

 Collaborative projects must include at least one investigator not named as personnel on the parent award who brings unique expertise required for the proposed project. 

• The proposed research plan must be within the overall scope of the active NCI-funded D43, U54, U01, R37, R33, R41/R44, and/or R01/R21 award and align with the priorities of the Center for Global Health. 
• At least one applicant must hold an active grant or cooperative agreement in one of the following CGH networks:
  • Global Implementation Science for Equitable Cancer Control (GloballSE Cancer Control) - RFA-CA-22-019
  • Affordable Cancer Technologies (ACTs)  - RFA-CA-22-020 and RFA-CA-21-030
  • Global Training for Research and Equity in Cancer (GlobTREC) -  RFA-CA-20-031
  • Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries - RFA-CA-21-056
  • Tobacco Use and HIV in Low and Middle-Income Countries RFA-CA-20-037
  • Investigators supported through NOSI: Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments (NOT-CA-22-038 and NOT-CA-20-025) are eligible if they submit a collaborative supplement application with investigators funded on the networks above.
• Supplements to parent awards that include multiple program directors/principal investigators (PDs/PIs) may be requested by any or all of the PDs/PIs on that award (in accordance with the existing leadership plan) and must be submitted by the awardee institution of the parent award. 
• Early-stage investigators (ESIs) and/or investigators from LMICs, as defined by the World Bank, are strongly encouraged to apply as part of collaborative teams.

Budget:

1. Supplement budget request must reflect the actual needs of the proposed one-year project and are limited to $100,000 direct cost per project (e.g. for a collaboration between two CGH-led or co-led program awardees, each could request up to $50,000 in direct cost; for a collaborative project that includes a sub-contract, the parent CGH research program award could request up to $100,000 in direct cost to support the collaboration).
2. The parent award must be able to receive funds in FY24 and be active throughout the 1-year project period. The parent award must not be in an extension period (e.g., cost or no-cost extension).
3. Where supplement funds are being requested by more than one collaborating grantee institution, each institution should submit an independent application using the same Research Strategy section but provide independent budgets that together does not exceed $100,000 direct cost.
4. At least one full year on the parent grant must remain at the time of funding. The supplement application budget is limited to one year only.
5. The earliest anticipated start date is August 1, 2024.
6. Requests for no-cost extensions on the parent grant to accommodate a supplement will not be permitted.
7. If the budget includes a request for salary support, it should include a justification and clear details on what each person will be responsible for. If supporting students and/or postdocs, please indicate if they are already working in the lab or when they will be recruited. A description of how the student/postdoc will be supported after the conclusion of the one-year supplement must be included. Including support for a patient or research advocate or community partner to collaborate on a supplemental project is acceptable.
8. The administrative supplement awards pursuant to this opportunity are contingent upon the availability of funds from NCI and the receipt of a sufficient number of meritorious requests.

Submitting Applications:

1. Application Due Date: All requests, regardless of parent award funding mechanism, must be received by 5:00 PM local time on May 22, 2024. The NOSI will expire May 23, 2024. This is a one-time announcement - late applications will not be accepted.
2. The supplement application title should be distinct from that of the parent award and should reflect the content of the supplement proposal.
3. Applicants should begin the supplement application abstract by stating “This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA-24-039.”
4. For funding consideration, applicants must include “NOT-CA-24-039” (without quotation marks) in the Agency Routing Identifier field (box 4b) of the SF424 R&R form. Applications without this information in box 4b will not be considered for this initiative.
5. Page limits: The Research Strategy section of the application is limited to 3 pages (excluding references).

Review and Selection Process:

NCI will conduct administrative reviews of applications and will support meritorious applications submitted for consideration based upon the availability of funds.

There is no limit on the number of applications from each awardee that can be submitted in response to this NOSI, but NCI will prioritize supporting applications from multiple groups across the CGH networks over multiple supplements tied to any individual award.

Specific Review Considerations

NIH staff will consider the ability of the proposed supplement activities to increase the parent award’s overall impact within the original scope of award and the overall contribution of the collaborative project to program priorities. It is highly recommended that potential applicants contact their NCI Program Director before applying to ensure collaborative projects reflect program priorities.

Other  considerations that will be considered during review include:

1. The significance of the specific question being pursued within the collaborative project;
2. The requirement for and importance of equitable collaborative research to accomplish the goals of the project;
3. A rigorous study or experimental design with adequate plans to address impactful global cancer research;
4. The applicability of the approach to requirements from the NOFO to which the parent application was submitted (e.g., for an application originating from the ACTs program, does the approach focus on the development or validation of technology suitable for LMIC settings?);
5. A realistic scope of work, given the time and budget requested.

Non-responsive Applications

Requests for support of clinical trials will not be accepted and/or considered in response to this NOSI.

Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission. 

Inquiries

Please direct all inquiries to:

Fatou Jallow, Ph.D.
National Cancer Institute (NCI)
Telephone: 202-253-9339
Email: [email protected]

Margarita Correa-Méndez, Ph.D., MPH
National Cancer Institute (NCI)
Telephone: 227-215-4638
Email: [email protected]